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INTRODUCTION
Medical history has proved that successful and
efficient treatment of a disease often awaits a clear
understanding of the pathogenesis of the disease.
Examples include acute appendicitis, diabetes mellitus,
and the various vitamin deficiencies.

Although a

knowledge of the pathogenesis of a disease does not
guarantee an automatic unveiling of the secrets of
therapy, this knowledge will allow a methodical search
for these secrets.
The knowledge of the detailed etiology of myasthenia
gravis remains sketchy despite much well planned and acceptably executed research.

Although the present day

therapy of myasthenia gravis must not be underrated, it
is not unreasonable to hope that more satisfactory
treatment might follow more exact etiological knowled,zer
While, we can contribute no laboratory work to the
elucidation of the problem of the pathogenesis of
myasthenia gravis, we can correlate and evaluate work
done by others and perhaps make some conclusions from
the available data relative to the subject.

It is

believed that a thesis with this purpose, carefully done,
will have some merit.

-

Preliminary to and as a basis for the more detailed
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discussion of the problems of nature and pathogenesis,
a general discussion of the disease will be undertaken.
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DEFINITION AND HISTORY
Myasthenia gravis is a disease or syndrome
characterized by weakness, fatigue, and less commonly
wasting of voluntary muscles, particularly those
supplied by the cranial nerves.

The disease, there-

fore resembles bulbar or bulbar-pontine palsies on the
one hand and the muscular dystrophies on the other.

The

etiology of the disease is unknown, and the pathology
is inconstant and variable.
Guthrie (1) believes that a description by Thomas
Willis (2) in 1685 can hardly be of any other disease
than myasthenia gravis.

Wilks' (3) case of "bulbar

paralysis" is generally considered to be the first case
on record.

However, in 1875 Gowers (4) reported a

typical case but did not credit the case to myasthenia
gravis (see his manual, i, 1899 p. 587, footnote).
More complete work was conducted by Erb (5) who describes
"A new, probably bulbar, ,;roup of symptoms."

The disease

was not clearly delineated, however, until after the
articles of Goldflam (6) in 1893 and Jolly (7) in 1895.
Jolly proposed the name "myasthenia gravis" which has
persisted as the name of the disease.
More complete history of various phases of the
disease will be presented in the parts of the thesis
devoted to those phases.
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ETIOLOGY
There is a trivial preponderance of occurence in
the female over the male (142 in Starr 1 s (8) series of
250).

The disease, however, tends to strike women

earlier in life than men; the average of women 1 s age
at onset was 24 years as compared to that of men at
35 years in the 56 case series of Campbell and Bramwell
(9).

Age incidence is shown in Table I in the series of
Gerstle (10) and that of Booth (11).
Age Incidence
Gerstle

Booth
Decade

Number

1-10
10-20
20-30
30-40
40-50
50-60
60-70
70-80

5
34
85

58
40
12
6
1
241

Percentage
2.0
13.6
38.0
23.2
16.0
4.8
2.8

o.e

Number
2
12
31

a

13
1
0
0

Percentage
3.0
18.0
46.2
12.2
19.0
1.5

6'?

'JJABIIE I
(From Wilson (12), Neurolo~y)

In both series maximum incidence occurs in the
third decade, and this incidence then decreases with
inc-ceasing age.

-

Myasthenia gravis is rare in children.

The first:.
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case in childhood was reported in 1892 by Remak (13).
Other cases reported in children include that of
Gowers (4) 1902; Roussy and Rossi (14) 1911; Gerstle
(15) 1929; Ziegler (16) 1930; Nelson (17) 1935; Rothbart
(18) 1937; Kawaichi and Ito (19) 1941; Levethan, Fried,
and Madonick (20) 1941; and Lieberman (21) 1942.

The

case of Kawaichi and Ito occurred in a 21 month old
infant.

The diacnoses of the cases after 1936 were

confirmed by the nprostigmine test" of Viets and Schwab
(22).

In the older age group the disease has been

diagnosed at age 71 by Hingston and Stoddart (23) and
at age 69 by Keschner and Strauss (24).
Heredo-familial incidence is generally not considered to be a factor but is suggested by several
recorded cases.

Marinesco (25) reported cases in two

sisters in 1908; Hart (26) reported cases in two
siblings in 1927.

In 1942, Riley and Frocht (27)

reported the incidence of myasthenia gravis in two sisters
with onset at ages of 11 and 14~

Strickroot, Schaeffer,

and Bergo (28) in 1942 report a c~se of myasthenia gravis
in a baby (confirmed by prostigmine test) born of a
myasthenic mother.

The baby died during the first year

of life, and at autopsy, the brain showed pathology

-

suggestive of encephalitis.
Social and occupational factors exert no influence.

-
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No race is immune.

The case of Kawichi and Ito (19)

occurred in an oriental infant; that of Lieberman (21)
in a colored child of five years.
Healthy subjects are often attacked rather suddenly, so that infections (29), toxemia, overwork, chill,
and electric shock (30 and 31) may be implicated and
perhaps rightly so •. Pregnancy may be connected with the
development of myasthenia gravis.

Punton (32) and

Frieberg (33) reported cases beginning during pregnancy
and soon after delivery.

The influence of pregnancy

on the course of the disease will be considered later.
The occurrence of myasthenia gravis with hyperthyroidism and goiter m&.y be more than coincidental.
The first case reported was that of Rennie (34).

In

his case both diseases improved after thyroidectomy.
Kowallis, Haines, and Pemberton (35) reported three
cases.
r

Other cases were reported by Thorner (36) and

Cohen and Kling (37).

Thorn and Tierney (38) found

that iodine will decrease the creatine tolerance in
thyrotoxicosis but not in myasthenia gravis.

They

believed this would be helpful in evaluating the extent
to which the disorder in thyroid function aggravated
the symptoms of myasthenia gravis in patients with both
diseases.
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SYMPTOMATOLOGY
Tlie symptomatology of myasthenia gravis is quite
generally known but will be reviewed.

The onset is

usually insidious, and even though a particular symptom
may appear suddenly, progression is generally slow.
Lieberman (21), however, reports a case in a five year
old child with fulminating onset and early respiratory
difficulty.

The muscles receiving their motor supply

from the cranial nerves are commonly the first to become weak, althoueh the weakness and tiredness may begin
in the limbs or diffusely all over the body.

The chief

disturbances are motor weakness, but pains, aches, and
paraesthesiae may be present.,
Tfie patient usually experiences abnormal fatigue
before he notices loss of power.

However, a patient will

rarely seek medical help until motor weakness appears,
because only then does he suspect a serious disorder.
The characteristic feature of the fatigue is the speed
with which it is produced by repetition of movement.
The patient begins to talk and,.his voice soon becomes
husky, nasal, and feeble until anarthria and aphonia
supervene.

An index of the severity of the disease

may be the distance the person can count (12).

Milder

cases of myasthenia gravis may not have symptoms until
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late in the day.

Wilson (12) describes the fatigabili-

ty of the myasthenic as ncrescendo fatigability."

This

crescendo fatigability is also noticed in writing,
feeding, walking, chewing, and swallowing.
dysphagia may be the presenting symptom.

Indeed,
The trunk

muscles are less commonly involved early, but they are
not immune to the process.

Quiet breatning may cause

no difficulty, but the patient is often unable to
execute a series of deep inspirations and expirations.
Difficulty may be experienced in sitting upright or
in supportinr the head.

Also characteristic of the

fatigability is its improvement by sleeping or resting.
Some patients sustain the day by alternating periods of
rest with periods of activity.
Generally it is considered that fatigue and loss
of power effect the same muscles.

Curschmann thinks that

failure of power is characteristic of muscles of the face,
shoulder, and those of the pelvic girdle; that fatigue
is characteristic of ocular, laryngeal, jaw, and distal
limb muscles.(39).

Wilson (12), however, does not agree.

Some do not believe that weakness and fatigue are separate
symptoms; that weakness is merely a result of the abnormal
fatigue of the muscle.

-

However, poor contractions are

obtained even when the muscle group is thoroughly rested.
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Activity of one set of muscles may tire others (40 and
41).

This is also true of physiological fatigue, but

the abnormal fatigability of the myasthenic muscle
allows the fatigue to become manifest.
In some cases the weakness remains amazingly
localized.

Gavey (42) reports a case in which ophthalmo-

plegia was the only manifestation of the disease in over
25 years of observation.

The diagnosis was confirmed

by the prostigmine test. · Sniderman (43) also reports a
case with only ophthalmoplegia •.
In advanced cases, paralysis may be complete and
appear to be permanent.

Muscular atrophy is more

common than is generally implied, being noted in 28
of 200 cases by Markeloff (44) and has been observed
personally in one case.

Wilson (12) describes a

"myasthenic tongue" characterized by a triple longitudinal furrow; one running along the raphe on either side
midway between the raphe and the lateral edge.
fibrillation is rare as might be expected.

Muscular

Tonus is

not changed generally but in severe cases may be somewhat decreased.
The constancy of the muscles involved causes
myasthenics to look very much alike; that:is; they have

-

the myasthenic facies.

Ptosis on one or both sides is
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almost constant, and as has been mentioned may be the
only symptom.

This ptosis makes the patient look

sleepy, and Wilson (12) has observed that the eyelashes
may lose their upward curl and accentuate the appearance of drowsiness.

Hardie (45) reports a case of

myasthenia gravis ope,rated on for ptosis by the Hess
operation.

Ophthalmoplegia of one type or another is

nearly as constant as ptosis.

Hart (26) reports

myasthenia gravis in sisters, both of whom had ophthalmoplegia.

Walker (46) reported a strange case in which

fatigue of the fore-arm muscles caused transient
ophthalmoplegia.

This illustrates the transmissability

of fatigue already mentioned.

Barron (47) illustrated

the efficacy of prostigmine methylsulfate by the
comvlete relief of complete ophthalmoplegia of two months
duration within five minutes.

Power of convergence is

usually lost earliest and is the power most commonly
lost; vertical movement is next most vulnerable •. Diplopia
is also an early symptom.
The nasolabial and frontal folds of the face often
disappear so that the face aquires a smooth appearance
usually described as "ironed out."

This added to the

ptosis tends to give the myasthenic an insipid look.
The mouth hangs open somewhat and the lower lip becomes

--
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everted.

Tne myasthenic smile is more nearly a snarl;

the patient realizes this to his embarrassment and
usually covers his smile with his hand.

Wilson (12)

points out that the zygomatics and risorious are paralyzed while the levator labii superioris and anguli eris
are intact so that the corners of the mouth are not drawn
up while the levators expose the canines.

Masseter

weakness causes the mouth to hang open or be supported
by the hand; palatal paresis makes the voice nasal and
allows fluids to pass into the nose during deglutition.
Weak laryngeal, inter-costals, sterno-cleidomastoids, and diaphragm muscles produce dyspnea which
may be fatal.

Dyspnea may occur sponte.neously or be

precipitated by exertion.

Laryngeal weakness may be

confined to adductors or one vocal cord.

Weakness of

superior pharyngeal constrictor muscles impedes
swallowing and makes choking a constant danp;er.
A few cases show involvement of muscles of the
neck, trunk, and extremities first (48).

Unilateral

bulbar myasthenia is recorded by Heernu (49).
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SIGNS

Usually normal faradic and galvanic responses are
obtained initially, but sometime-is a stronger galvanic
current is needed than normal to produce a twitch.
Jolly (7) in 1895 described the nmyasthenic electrical
reaction" which essentially is rapid tiring of the
muscle with maintenance of faradic stimulation or upon
rapid repetition of individual shocks.

If the muscle

·is allowed to rest it will contract again.

If the

muscle is fatigued by interrupted shocks it will still
react to continuous stimulation or to voluntary use.
Also a muscle fatigued by voluntary contractions will
react to faradic stimulation •• Frequency of stimulation
determines the extent of the contr~ction and not the
strength of the current.

Pritchard (50) found that the

myasthenic muscle stimulated 220 times per second lost
tension rapidly.

The reaction is not proportional to

the severity of the disease and may be present at one
time and absent at another.

A muscle may show the reac-

tion yet contract strongly; a weak muscle may not show
the reaction.

The reaction may be found in brain tumor

and polyneuritis.
Sensory organs are not affected.

~acquini, Cooke,

and Schwab (51) observed 14 cases and decided that the
cardio-vascular system was normal in all.

Psychical
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disturbances do not form a constant part of the syn:irome
but have been reported several times.

Jelliffe (52)

suggested that extreme unconscious hostility plays a
part in the syndrome.

Kennedy and Moersch (53) do not

believe that there is a specific emotional disturbance,
but in seven cases of 87 observed, there were anxiety
and depression with one suicide.

Tliey called attention

to the fact that symptoms of chronic fatigue in myasthenia
gravis were often misinterpreted as neurasthenia or other
psychoneurosis.
a case.

Indeed Collins (54) reported just such

Boothby (55), Buzzard (56), and Keschner and

Strauss (24) also reported cases with depression and
suicidal trends.

Hayman (57) cites an interesting case

in which a patient explained his own myasthenic symptoms
by delusions.

On the other hand Hun (58) and Oppenheim

(59) state specifically that mentL.l abncrmali ties play
no part in the dis~ase.
Laszlo and Redlich (60) believe that changes in
vital capacity parallel closely the alterations of the
general state.

They used measurement of vital capacity

as a determination of the severity of the disease or
the efficacy of treatment •.. They found no interference
with oxygenation of the blood.

Tfiey also used improvement

of diaphragmatic excursion (as observed fluoroscopically)

as a measure of improvement with therapy.
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CLINICAL PATHOLOGY
Blood and spinal fluid are practically always
normal.

The studies reported are often contradictory.

Increase in lactic acid in the blood and urine is reported by Mohr (61) an:i von Bergmann and Dresel (62)
but denied by Diller and Rosenbloom (63) and Spriggs
(64).

Excess of serum calcium (65 and 66), normal

amount, and decrease (67) have all been reported.
Normal blood su~ar (68) and hyper- or hypo-glycemia
are all reported.

Adams and Power (69) in studying

the effect of glycine on the metabolism of myasthenia
gravis state that calcium, sodium, magnesium, potassium,
phosphorus, sugar, urea, creatinine, amino acids, and
uric acid are all found in the blood in normal amounts.
Creatinuria was found by Williams (70) in four cases
subjected to a creatine-creatinine free diet.

Only six

of the 28 cases of Adams, Powers, and Boothby (71)
showed a creatinuria; there was little correlation
between the creatinuria and the severity of the disease._
Administration of glycine by mouth, however, would
produce creatinuric. in every c&se.

Wilder (72) found

that glycine also increased creatinine excretion if
there was clinical improvement, but failed to do so
without improvement.

Meredith (73) and Milhorat and

-
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Wolff (74) conclude that creatine excretion in the
urine will only be founl. in rather severe cases of
myasthenia gravis and that it is the result of the
disease rather than a factor in its cause.

Nevin (75)

found no characteristic chemical change in excised
myasthenic muscle.
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PATHOLOGY
Many cases of myasthenia have been autopsied
.without significant findings while others have shown
clear-cut pathologic lesions.
of the disease.

This adds to the mystery

Tl'J.e most constant change is the "lympho-

rrhage, n so named by Buzzard (56) in 1905.

According

to Wilson (12) these lesions had perviously been described by Sossedort (1896), Weigert (1901), Hun (1904),
and others.

Tliese lymphorrhages are collectior~ of

lymphocytes most oft~n found in muscle but also found
in other parts of the body.

Weigert (76) thought these

lymphorrhages were metastases from the thymus.

Rottino,

Poppitto, and Rao (77) report a case in which diffuse
myocarditis and focal mural endocarditis were found.
The lesions of the myocardium were lymphorrhages.
Lymphorrhages may also be found in the liver, lungs,
salivary glands, endocrine glands, and other viscera.
In the muscle they are found both within and outside
the muscle fibers.

Wilson (12) does not believe their

presence or extensiveness bears any relation to the
course or severity of the disease.

Myasthenic muscle

may undergo fatty infiltration or fatty degeneration
or show other degenerative changes.

-

to the lymphorrhages.

This may be related
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Probably the next most common pathological lesion
in myasthenia gravis is the presence of a persistent,
hyperplastic, or neoplastic thymus.

Weigert (76) was

the first to observe an enlarged thymus g1£md in
myasthenia ~ravis (1901).

Bell (78) in 1917 reviewed

autopsy records of 56 cases of myasthenia gravis; 27
of these showed abnormalities of which 17 were hypertrophy and 10 neoplasia.

Alter and Osnato (79) report

myasthenia gravis with status lym1,haticus and multiple
thymic grccnulations.

Norris (80) studied 80 necrovsy

reports and found records of thymic lesions in 35 cases.
He expressed the opinion that thymic abnormalities are
found in direct·ration to the care with which they are
sought.

Blalock, Mason, Morgan, and Riven (81) have

reviewed more cases of thymic abnormalities anu are
impressed by the relationship of the thymus to myasthenia
gravis.

The neoplastic thymus tissue may be benivn

thymoma, lymphosarcoma, thymic carcinoma, or lymphoepithelioma,

Skinner (82) reported a case of myasthenia

gravis with multiple lymphomata; Miller (83) presents a
study of the thymus and myasthenia gravis and believes
there is a definite relationship.
Rosenow and Heilman ( 84 and 85) believed that
streptococci were involved in the etiology of myasthenia
gravis.

Butt (86) also reports the demonstration of
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of streptococci in the muscle fibers.

Atrophic adrenals and lesions of other ductless
glands have been described.
McAlpine (87) described a case with microcytic
infiltration of the cord.

Barrada (88) describes a

case with general reduction of basophil cellular material
and replacement by lipoid material in the central nervous
system.

Much oftener, however, no lesion is found so

that lesions when found are more liable to be incidental
than related.

-
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DIAGNOSIS
A well-marked case of myasthenia gravis can be
recognized by the facies, smile, tongue, ocular paresis,
and nasal voice,

very valuable,

The history of crescendo fatigue is
Thymic hyperplasia as demonstrated by

roentgenoloe,y may be helpful, and muscle biopsy may
show the characteristic lymphorrhages,

However, in

early cases the diagnosis is difficult to establish,
As has been mentioned, the early symptoms are often
ascribed to psychoneurosis,

Fugitive diplopia makes

distinction from multiple sclerosis difficult.

Loss of

abdominal reflexes points to multiple sclerosis in
which also nystagmus is more common than ocular palsy,
If the syndrome begins in the trunk and extremities it
may be necessary to await bulbar signs,

Spinal fluid

examination will differentiate myasthenia gravis from
bulbar lesions of epidemic encephalitis,

Occ1lar palsies

do not accompany facial muscular dystrophies.
The most important aid to diagnosis of myasthenia
.:;ravis was contributed by Viets, Schwab, and Mitchell
(89, 90, ani 91), the first article being published in
1935.

Harvey and Whitehill (92) and 3ammon and Scheie

(93) approved the test in 1937,

The test consists of

the hypodermic injection of prostigmine methylsulfate
(1,5 mg,); in myasthenia gravis the symptoms will be
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relieved within a few minutes.

Tliis test is specific,

in that no other condition will be relieved so promptly
if at a1i by prostigmine.

Atropine sulfate (.6 mg.)

may be added to the prostigmine to prevent sastrointestinal effects.

This test has greatly simplified

the diagnosis of myasthenia gravis.

Harvey and Whitehill

(94) added a test with quinine (the quinine aggravating
the symptoms of myasthenia gravis) as an adjuvant to the
therapeutic test with prostir,mine.

The quinine test is

not without danger, however, as quinine added to
myasthenia gravis may cause respiratory paralysis,
Levy (95) believes that a case of progressive
muscular weakness should be diagnosed as myasthenia gravis
if an appreciable trace of urinary creatine is found.

He

believes the creatine output closely parallels the clinical
symptoms.

Bennett and Cash (96) describe a curare test;

curare, like quinine, aggravates old symptoms and may
produce new ones.
methylsulfate.

The test is termina.ted with prostigmine

Tiie apparent danfer of this test is made

somewhat less re~l by the possession of the specific
antidote of curare; prostigmine.
Schwab and Viets (97~ believed that the fluoroscopic
observation of the swallowing of barium before and af'ter
prostigmine was a valuable aid in diagnosis.

-
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PROGNOSIS.
In the earlier stages of the disease remissions
are quite frequent and may be hoped for, but later
most of the symptoms become fixed,

Tl'le disease may

be present over a period of 20 or more years or may end
fatally within a year,

Most commonly, however, the

duration is five to 10 years,

Relapses are naarly as

characteristic of the disease as remissions,

Severe

dyspnea and respiratory failure may produce death
quite unexpectedly.
Child-bearing may affect the course of the disease,

Sinkler (98) in 1899 reported the first case of

myasthenia gravis in pregnancy; in this case the
patient improved with i;regnancy,

Goldflam (99) in

1902 watched one myasthenic through three pregnancies
and implied that she improved with each,

He told her

that she should always be pre~nant to remain in good
health,

Reuter (100) and Milhorat (101) also report

cases of improvement with pregnancy,

SYmptoms may

remit during one pregnancy, recur in the puerperium
and remit again in the next pregnancy,

However, Kohn

(102), von Hosslin (103), Warrington (104), Genmell
(105), Indemans (106), Tilney (107), Wolff (108) and
Tabachnick (109) report cases in which pregnancy had
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an unfavorable effect on the disease.

Laurent (110)

reported cases both favorably and unfavorably influenced by pregnancy.
Viets, Schwab, and Brazier (111) after reviewing
the literature and their own experience concluded that
most patients have a definite remission in symptoms.
According.to them, relapses may occur in the first
trimester with remissions later in pregnancy which last
for three to six months after presnancy.

They believe

that therapeutic abortion is never necessary with
present methods of treatment and that the second
pregnancy is no more hazardous than the first.
Newer methods of treatment seem to lessen the
mortality and improve the course of the disease.
Oppienheim (59) in 1904 reported 38 cases with 26 deaths
while Boothby 1 s (112) summary of 46 cases in 1934
observed 26 months showed the following:! 13 returned to
business, 9 greatly benefited and doing light work, 17
moderately improved, and seven dead.

It should be noted

tha.t this re;;ort appeared only four years after the
advocation of ephedrine for treatment and.Before the use
of prostigmine.

Viets and Schwab (113) in 1939 reviewed

the experience at Massachusetts General Hospital since

-

1905.

From 1905-1934, 31 patients were diagnosed as

myasthenia gravis of which seven died quickly and they

-
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From 1935-1939 (after prostigmine) there were 44 cases
in which prostigmine we,s used orally from a few months
to two and one-half years.

In these 44 there were five

deaths (four over 50 years of age; one 27).

This indicat-

ed an even more favorable prognosis since prostigmine.
Whether permanent cure is ever accomplished is
doubtful; the greater the asthenia the less favorable
the outlook.

-
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TREATMENT
Treatment prior to 1930 was principally palliative
and symptomatic.

The principles of treatment evolved

then, however, still have their place and are to be
used in conjunction with specific therapy.

Mental and

physical rest are necessary no matter how moderate the
symptoms, care being taken to rest especially the muscles
most affected,

Complete bed rest, however, is not

required unless fatigue is profound,

The patient should

be assured that his condition is not hysterical and
that he must not "fight" the disease,

Massage, exercise,

and electrical stimulation are useless and may be harmful,

If dysphagia is a symptom, food should be minced

or otherwise prepared in a soft form,
taken between rnouthsful of food,

Rest should be

TUbe or spoon feeding

may be required in severe cases, but the tube must
always be passed very carefully,
Various tonics have been recommended, but probably
are not very useful,

Dana (114) in 1922 and Jackson

and Bates (115) in 1923 recommended large doses of
strychnine,
More satisfactory progress in the therapy of
myasthenia gravis began in 1930 when Miss Harriet

-

Edgeworth (116 and 117), a physician and victim of the

-
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disease, discovered the efficacy of ephedrine.

She

took 6/8 grain of ephedrine sulfate daily for three
years and was transformed from a ntotally helpless
personn to one "living a comparatively comfortable and
pleasant life of some usefulness.n

The efficacy of

ephedrine was soon confirmed by McAlpine (118) and
Swan (119).

No satisfactory explana.tion of the mode of

action of the drug has ever been given.
In 1932 Boothby (120) published a preliminary
report on the use of glycine (amino-acetic acid; glycocoll) in therapy of myasthenia gravis.
lowed in 1933 by a second raport (121).

This was folIn 1934 Boothby

(122) recommended combination of glycine and ephedrine
in therapy.

Slnce then many articles have appeared on

the use of glycine.

Most of these articles have come

from the Mayo clinic and while the efficacy of glycine
is still in doubt, much valuable information of the
metabolism in myasthenia gravis has resulted from this
work.
day.

Boothby recommended 10 grains three times each
The drug supposedly has a prolonged effect and while

apparently very efficacious in some cases, does little
or nothing in others.

The mode of action of glycine is

unknown, but it is believed to effect creatine metabolism.

,-

Walker (123) was impressed by the resemblance between
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myasthenia gravis and curare poisoning, previously
mentioned by Oppenheim (124).

Knowing the pharmacol-

ogical antagonist of curare to be physostigmine, she
tried physostigmine and found it produced rapid improvement.

She later found prostigmine to be better suited

to the therapy of myasthenia gravis (125).

Confirm-

atory reports came immediately from Pritchard (126)
and Laurent (127) and since these early reports, many
cases have been reported to be benefited by prostigmine.
Prostigmine bromide tablets, 15 mg. are generally used.
As many tablets as are necessary may be taken.

Pro-

stigmine methylsulfate for intramuscular or intravenou.s
use is usually reserved for respiratory crises.
Slnce potassium chloride stimulates the cells of
the cervical sympathetic ganglia in the cat and raises
their excitability to acetylcholine, Laurent and
Walther (128) tried large doses in myasthenia with
somewhat encourar,ing results.
In 1938 Minot, Dodd, and Riven (129) introduced
guanidine hydrochloride as a therapeutic agent in
myasthenia gr~vis.

The mode of action of the drug is

not known, but it is believed to favorably affect
muscle metabolism •. They found an increased tolerance
to guanidine hydrochloride in patients with myasthenia
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gravis.
Many other therapeutic agents have been tried-most of then endocrine preparations.

Apparently they

have little or no value and sincls reports of favorable
action can not be differentiated from remissions which
would have occurred without treatment.
~nother phase of treatment in myasthenia gravis
is concerned with the teymus and consists of either
irradiation or surgical extirpation.

Although no

proof' exists that the thymus is a fe.ctor in the etiology

of the disease, its presence in abnormal form in about
50 per cent of cases is strongly suggestive.

Eaton (130)

tells of Adler's work with the teymus which also suggests
a relationship between the thymus and myasthenia gravis.
Adler transplanted the thymuses of puppies and calves to
mature dogs and by injecting extracts of calves'
thymus into docs he claimed to have produced weakness
resembling myasthenia gravis and the myasthenic reaction
to faradic current characteristic of the disease.
Prostigmine temporarily abolished the reaction and the
weakness.

Support to the possibility of a relationship

between the teyrnus and myastherda gravis is also lent
by the work of Harvey, Lilienthal, and Talbot (131).

TI'.ley restudied five patients with severe myasthenia

-
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gravis up to five months after total extirpation of

the thymus.

Three of these patients showed great clin-

ical improvement and coincident to this improvement
the electromyographic,reaction and the reactions to
intra-arterial injection of acetylcholine and prostigmine approached normal.
Blalock is the champion of thymectomy in myasthenia
gravis and completely reviewed the literature on the
subject.

The first case of thymectomy was performed

by Sauerbruch (132) in 1912.

The patient had thyro-

toxicosis and myasthenia gravis.

He first ligated the

superior thyroid artery, then did a thymectomy, then a
thyroidectomy.
was noted.

Some improvement in the myasthenia

Blalock (133) obtained excellent results

in three cases of six opecated and believes that all
cases should be explored for thymic tissue even though
none is evident on roentgenological examination.

True

evaluation of the thymic extirpation or destruction
must await further experience which seems to be forthcoming.

The most recent articles on myasthenia r,ravis

are predominately devoted to the relation of the thymus
to the disease.
Ea,ton (134) in 1941 recommended a procedure of
treatment which conforms to modern concepts.

He suggest-

ed findin~ the minimum daily requirement of prostigmine

-
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bromide taken orally, spaced so that maximal strength
will be obtained when maximal effort is to be expended.
The tablets are 15 mg. each; two to 20 tablets may be
taken daily.

Atropine sulfate may be given to decrease

nause&, vomitin,;, abdominal cramps, and diarrhea.

Having

found the minimum daily requirement of prostigmine,
ephedrine, potassium, and guanidine in turn with
prostismine.

If arw seems to be useful, it may be used

also.
Ephedrine is used in doses of 1/8-3/8 grain twice
to three times daily, the last dose being given not
later than four o'clock in the afternoon.
Guanidine hydrochloride in 125 mg. tablets are
available and the dosage is 10 mg •. per kilogram of
body weight.

The effect of guanidine is not as vicor-

ous as prostigmine, but the let down feeling does not
occur when it wears off.

Toxic symptoms are nervous-

ness, anorexia, nausea, and diarrhea.

These occur at

a blood level of .5-.6 mg. per 100 cc.

Some patients

can take 16 tablets per day.

Numbness and tingling of

the upper extremities frequently occur with guanidine
and the patient should be reassured regarding this
symptom before treatment is initiated.

-

Potassium chloride is given in daily doses of 20
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to 40 grams in three or more doses (25 per cent solution
or in milk after meals).
intestinal symptoms.

There may be severe gastro-

Paraesthesias develop with a blood

level of over 30 mg. per cent.

Diuresis is to be

expected.
Eaton believes that enl rged thymus should always
be looked for by chest plates.

He believes in irradia-

tion of the thymus, which, if remission occurs within
two or three months, should be followed by complete
surgical extirpation.
Salzer (135) recommended sublingual administration
of prostigmine bromide in cases where prostigmine
methylsulfate is not available and action more rapid
than can be obtained orally is required.

-
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NATURE AND PATHOGENESIS
As stated in the introduction, the principal
purpose of this thesis is the consideration of the
nature and pathogenesis of myasthenia gravis in an
attempt to draw some conclusions from the work that
has been done.

Preliminary to the discussion of experimentation
with myasthenia gravis the accepted facts concerning
neuro-muscular chemo-transmission will be discussed.
It is known th:~t nicotine will stimulate autonomic ganglia or the neuro-muscular junction of
voluntary muscle before it paralyzes.

Thus aey drug

that has a stimulating effect at the ganglia or neuromuscular junction of voluntary muscle is said to have
a nicotinic effect.

Muscarine stimulates structures

innervated by post-ganglionic parasympathetic fibers,
so that drugs with a similar action are said to have

a muscarinic effect.
In 1914 Dale (136) was impressed by the remarkable
similarity between the actions of injected acetylcholine
and parasympathetic stimulation; he introduced the term
"parasympathomimetic" to describe the effects of acetylcholine.

In 1921, Loewi (137) proved the chemical

mediation of nerve impulses by the peripheral release
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of specific chemical agents.

Feldberg and Krayer (138)

in 1933 further established the role of acetylcholine
as a chemo-transmitter.
Figure I diagrammatically represents chemical
mediation in autonomic innervation.
Parasympathetic

Cl

::::?,.__ . . ('\
nicotinic ~ y [ c h o l i ne
effect

muscarinic
effect

Sympathetic
<. • ..:::::::.:

nicotinic /'
effect

<.....

acetylcholine

sympathin"

Somatic

m"'-------------<,11
Adrenal

t--

voluntary muscle
acetylcholine
(nicotinic effect)

/14- adrenal

medulla

m~-----------,t!l ~ epinephrine
acetylcholine

(into
blood stream)

F:1.gure .I
The intestine of the Tench illustrates the nicotinic
arrl muscarinic actions of acetylcholine (139) as well

.-

as the actions of curare am atropine.

The intestine

has both smooth and striated muscle layers, both of
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which are innervated by the vagus.

It is known th&t

curare will block the nicotinic effect of acetylcholine
and that atropine will block its muscarinic ctCtion.
The contractions of the Tench intestine after vagus
stimulation are recorded as shown in Figure II.

vagus

L

quick component of contraction
(striated muscle)

(\

slow component of contraction
(smooth muscle)

no drug

after curare

L

after atropine

after atropine
and curare
E!Lgure II

It was shown in 1932 by Stedman, Stedman, and
Esson (140) that an enzyme, cholinesterase is present

-

wherever acetylcholine is a mediator.

This enzyme
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destroys acetylcholine, thus allowing relaxation of
muscle after contr,.,ction.
Acetyl-beta-methylcholine (mecholyl) and carbaminocholine (doryl) act similarly to acetylcholine
and have been developed in the search for substances
more stable than acetylcholine in the body.
Pilocarpine is only cholinergic for the postganglionic parasympathetic fibers and thus has the
muscarinic effect.
Physostigmine (eserine) and prostigmine are
cholinercic, because they inhibit cholinesterase and
thus allow greater action from acetylcholine present;

these drugs have both muscarinic and nicotinic effects.
Potassium somehow stimulates structures innerve,ted
by cholinergic nerves.

Its action is not blocked by

curare or nicotine.
With these physiological concepts in mind it seems
that the clinical picture of myasthenia gravis mLrht be
produced by one or more of three abnormalities:
(1)

a deficiency of acetylcholine;

(2)

an excess of muscle cholinesterase; or

(3)

existence of some abnormal substance or metabolite with a curare-like action which elevates
the threshold of skeletal muscle to the effects
of acetylcholine.
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Concerning the first possibility, that of a
deficiency of acetylcholine, little work has been
done.

Probably this is due to the difficulty encount--

ered in such determinations.

It seems fair, however,

to reason that the striking improvement following
physostigmine or prostigmine would not .occur if there
were not enough acetylcholine produced.

'l.'Fle result of

prostigmine administration would be about as disappointing as the releasing of a "Jack-in-the-Box" only to
find that there was no

11

Jack" there.

Several investigators have thrown doubt upon the
second possibility of excess muscle cholinesterase.
Lucas a1tl coworkers (141), Mc~eorge (142), Hall and
Lucas (143), Milhorat (144), and Poncher and Wade
(145) all found the serum cholinesterase values in

patients with myasthenia gravis to be normal.

It must

be granted that serum cholinesterase may not reflect
the cholinesterdse level at the myoneural junction.
Jones and Stadie (146) found that cholinesterase activity
of an incised piece of affected muscle was essentially

the same as that of two specimens of normal muscle.
While these findings do not rule out the possibility of
excess muscle cholinesterase, it can at least be said
that they cio not l'oint toward this as the most likely
possibility.

-
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According to Harvey and Marslarrl (147), Oppenheim
(124) in 1901 first pointed out the strikiru; similarity
between the symptoms of partial curarization and those
of myasthenia gravis.

It was the observance of this

similarity which led Walker in 1934 to try physostigmine
(which she knew to be the pharmacological antagonist
of curare) in myasther~a gravis.

Her results were

gratifying and as has been mentioned form the basis of
modern treatment.
Harvey and Marsland (147) studied the electromyographic recordings in myasthenia gravis and found them
identical in all respects to those found in partial
curarization.

They found no similarity between the

responses found in myasthenia ,;ravis and those in
normal fatigue.

These authors point out also that the

clinical picture of myasthenia gravis is identical with
that of partial curarization.

The following description

of Burman (148) of the effects of curare when compared
to the clinical picture of myasthenia ,~ravis will bear
out this statement:
"Arry curare after its intravenous injection, has

its first effect on the musculature supplied by the
cranial nerves, then on skeletal musculature, and lastly
on the muscles of respiration.
"The initial symptom is invariably dizziness which
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becomes greater with greater doses •. As this dizziness
recedes, the upper eyelids become heavy, and finally
there is partial or complete, but very temporary,
upper lid droop.

Mistiness of vision which is some-

times experienced by the patient is entirely subjective.
Diplopia may be present by paralysis of the ocular
muscles.

The facial muscles are relaxed or paralyzed

to greater or lesser degree, with smoothing of the
expression of the face • • • • TI'le patient may have a
gripping sensation in the throat and a feeling of
difficulty in talking.

There are no constant pupillary

char~es, no nystagmus, no chanfes in pulse or blood
pressure.

Tii.e urine is unaltered.~

Later, with larger

doses, skeletal and finally respiratory paralysis will
occur.
Harvey and Marsland (147) also point out that
prostigmine, potassium, and guanidine (successful
therapeutic agents in myasthenia gravis) are all antagonistic to curare in their action.

They state, "It

would be fallacious to base an hyyothesis on either tb.e
similarity in clinical picture, in the electrical
response, or in the action of ..irugs, but when these
three features are considered together, it would seem
justifiable to speculate on the nature of myasthenia
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Brown (149) believed from his work on cats that
curare effected a neuro-muscular block by raising the
threshold of the muscle fibers for acetylcholine stimulation.
Bennett arrl Cash (131) suggested that the syrrlrome
of myasthenia r,ravis mic;ht be produced by a curarelike substance produced in the body.

They hypothes-

ized that this substance might be quaternary ammonium
base and that it might be produced by thymic overactivity.

The work of Harvey, Lilienthal, and Talbot

(131) and that of Adler as related by Eaton (130) has
previously been mentioned as suggestive of an etiologic
relationship between the thymus and myasthenia gravis.
The facts that abnormal thymus is fourrl in only about
50 per cent of cases and that persistent or abr~rmal
thymus may be fourrl without evidence of myasthenia
gravis are still difficult to reconcile with this idea.
Harris (150 and 151) reported that curare but
not beta-erythroiden hydrochloride had a marked inhibitory effect upon the cholinesterase activity of human

serum,

The degree of inhibition up to 60 per cent was

approximately pro~ortion~l to the amount of curare
added.

If myasthenia gravis is caused by a curare

poisoning as Bennett and Cash have proposed, why is the
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serum cholinesterase activity in myasthenia normal?
We might assume that the depression was caused by an
impurity since it is not produced by beta-erythroiden
hydrochloride.

At any rate, confirmation of this

finding should be awaited.

-
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SUMMARY AND CONCLUSIONS
Most of the data available seems to fit rather
well with the hypothesis that myasthenia gravis may
be a self-perpetuated curarization.

The regarding

of the thymus as the source of this "curare" is
probably somewhat less likely.

Enthusiasm must not

blind us to the fact that our information is sketchy
and that much of the d~ta available is liable to
challenge and a wide diversity of interpretation.
McIntyre and Kiili; (152) are engaged at present in an
attempt to isolate a quaternary ammonium base (the
basic structure of curare) from the urine of patients
with myasthenia gravis.

If their efforts are success-

ful a very stronc'. piece of evidence will have been
added to the problem.
At present we may only conclude that the suggestion
of Bernett and Cash as to the pathologic physiolo~y is
a very attractive one.

Until more data is available,

however, it must remain a suggestion.
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